Key Insights

Highlights

Success Rate

92% trial completion (above average)

Clinical Risk Assessment

Based on trial outcomes

Moderate Risk

Score: 40/100

Termination Rate

4.3%

1 terminated out of 23 trials

Success Rate

92.3%

+5.8% vs benchmark

Late-Stage Pipeline

13%

3 trials in Phase 3/4

Results Transparency

25%

3 of 12 completed with results

Key Signals

3 with results92% success

Data Visualizations

Phase Distribution

17Total
Not Applicable (8)
P 1 (3)
P 2 (3)
P 4 (3)

Trial Status

Completed12
Recruiting3
Active Not Recruiting2
Withdrawn2
Not Yet Recruiting2
Terminated1

Trial Success Rate

92.3%

Benchmark: 86.5%

Based on 12 completed trials

Clinical Trials (23)

Showing 20 of 20 trials
NCT07609303Not ApplicableNot Yet RecruitingPrimary

Feeding the Flame, One Day at a Time: Design and Acceptability of a Serious Game to Support Medication Adherence and Education for Pediatric Solid Organ Transplant Patients

NCT06937463Not ApplicableCompleted

Use of an Off-the-Shelf Exergame as an In-Bed Gamified Rehabilitation Intervention for Severely Deconditioned Inpatients: A Feasibility Study

NCT07614282Phase 1Not Yet Recruiting

Rituximab for PTLD Prevention in Solid Organ Transplant Recipients With EBV DNAemia

NCT05164016Completed

Evaluating Immune Response to COVID-19 Vaccines in Patients With Cancer, Transplant or Cellular Therapy Recipients

NCT06529536Phase 4RecruitingPrimary

Utilising Genotype Informed Bayesian Dosing of Tacrolimus in Children Post Solid Organ Transplantation.

NCT04613206Phase 2Active Not Recruiting

High vs. Standard Dose Influenza Vaccine in Adult SOT Recipients

NCT04331275Phase 2Active Not RecruitingPrimary

Viral Specific T-cells for Treatment of Viral Infections After Solid Organ Transplant

NCT05550298Recruiting

Multi-Center Molecular Diagnosis and Host Response of Respiratory Viral Infections in Pediatric Transplant Recipients

NCT03360682Phase 4Completed

Clinical Trial to Evaluate the Efficacy, Pharmacokinetics (PK) Interactions and Safety of Dolutegravir Plus 2 Nucleoside Reverse Transcriptase Inhibitors (NRTIs) in HIV-1-Infected Solid Organ Transplant Patients

NCT05663463Not ApplicableCompletedPrimary

Seasonal Influenza Vaccine High Dose Boosting in Solid Organ Transplant Recipients

NCT05968807Not ApplicableRecruitingPrimary

iParent2Parent Program for Parents of Pediatric Solid Organ Transplant Recipients

NCT03950414Phase 1Terminated

A Dose-Escalation Study Evaluating Safety and Tolerability of Viral-Specific T Cells Against CMV in Adult Solid Organ Transplant Recipients

NCT05121142Phase 1Completed

Study of Ruxolitinib for Acute and Chronic Graft Versus Host Disease

NCT04253548Not ApplicableCompletedPrimary

iPeer2Peer Pediatric Thoracic Transplantation

NCT04844489Not ApplicableCompleted

Study of the Humoral Response to SARS-CoV-2 Variants and of the Cellular Response After Vaccination Against COVID-19 in Immunocompromised People

NCT04721288Not ApplicableUnknownPrimary

REmote moBile Outpatient mOnitoring in Transplant 2.0

NCT05124509Completed

Immune Response to Third Dose of COVID-19 Vaccine in Solid Organ Transplant

NCT03327987Withdrawn

Early Flu Shots in SOT

NCT02165423Not ApplicableCompletedPrimary

Discharge to Home and Chronic Illness Care Pilot

NCT02464306Phase 4Withdrawn

Fidaxomicin Versus Standard of Care Therapy in Solid Organ Transplant Recipients With Clostridium Difficile Infection

Scroll to load more

Research Network

Activity Timeline